REMD 477

Drug Profile

REMD 477

Alternative Names: AMG477; REMD477

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer REMD Biotherapeutics
  • Class Antibodies; Antihyperglycaemics
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Type 1 diabetes mellitus
  • Preclinical Metabolic disorders

Most Recent Events

  • 13 Jun 2017 Efficacy data from a phase I trial in Type 1 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 20 Apr 2017 REMD Biotherapeutics plans a phase II trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (NCT03117998)
  • 01 Jan 2017 REMD Biotherapeutics completes a phase Ib trial in Type-1 diabetes mellitus in USA (NCT02715193)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top